INE2: A Protein Involved in Neuronal Excitability and Neurological Disorders

Target Name: INE2

NCBI ID: G8551

INE2

Other Name(s): Inactivation escape 2 | NCRNA00011 | inactivation escape 2

INE2: A Protein Involved in Neuronal Excitability and Neurological Disorders

INE2, or Inactivation Escape 2, is a protein that is expressed in the brain and is involved in the regulation of neuronal excitability. It is also known as "Training Stop" (Training Stop) protein, due to its ability to reduce the amount of neurotransmitters released by neurons during synaptic transmission. INE2 has been identified as a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression.

The protein INE2 is expressed in the brain and is involved in the regulation of neuronal excitability. It is a key component of the postsynaptic density protein (PSD), a protein that is responsible for the maintenance of synaptic strength and the stability of the neuronal network . INE2 helps to regulate the release of neurotransmitters from neurons, which is critical for the proper functioning of the nervous system.

INE2 is highly expressed in the brain and is found in various neural structures, including the cerebral cortical cortical and subcortical regions, the amygdala, hippocampus, and striatum. It is also expressed in the retina, where it is involved in the regulation of neuronal excitability.

The function of INE2 is to prevent the inactivation of neurons that are not needed at a given time. This is achieved by modulating the levels of neurotransmitters released from neurons, which allows neurons to remain active even when they are not receiving signals from other neurons. INE2 does this by interacting with a protein called TrkB, which is involved in the regulation of neurotransmitter release.

INE2 has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression. Studies have shown that INE2 levels are decreased in the brains of individuals with Alzheimer's disease and that TrkB activity is increased in these brains. This suggests that INE2 may be a potential drug target for the treatment of Alzheimer's disease.

Similarly, INE2 has also been shown to be involved in the development of Parkinson's disease. Studies have shown that INE2 levels are decreased in the brains of individuals with Parkinson's disease and that TrkB activity is increased in these brains. This suggests that INE2 may be a potential drug target for the treatment of Parkinson's disease.

Another study has also shown that INE2 may be involved in the development of depression. Studies have shown that INE2 levels are decreased in the brains of individuals with depression and that TrkB activity is increased in these brains. This suggests that INE2 may be a potential drug target for the treatment of depression.

In addition to its potential role in the development of neurological disorders, INE2 has also been shown to have potential therapeutic applications. For example, INE2 has been shown to be involved in the regulation of pain signaling in the brain. Studies have shown that INE2 can inhibit the release of pain-related neurotransmitters from neurons, which may have potential therapeutic applications in the treatment of chronic pain.

Another study has also shown that INE2 can modulate the activity of glial cells, which are a type of nerve cell that support and protect neurons. Studies have shown that INE2 can inhibit the activity of glial cells, which may have potential therapeutic applications in the treatment of neurodegenerative diseases.

In conclusion, INE2 is a protein that is involved in the regulation of neuronal excitability and is expressed in the brain. It has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression . INE2 may also have potential therapeutic applications in the treatment of chronic

Protein Name: Inactivation Escape 2

The "INE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets